Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Origin Materials and Avantium to Accelerate the Mass Production of FDCA and PEF for Advanced Chemicals and Plastics Business Wire - Tue Feb 21, 2023

Origin Materials, Inc. (“Origin” and “Origin Materials”) (NASDAQ: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable...

ORGN : 0.9143 (-1.20%)
ORGNW : 0.0560 (+0.18%)
AVTX : 11.54 (-0.86%)
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates Globe Newswire - Thu Aug 4, 2022

Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received...

AVTX : 11.54 (-0.86%)
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II) Globe Newswire - Tue Aug 2, 2022

Topline Pivotal trial results expected 1H2023...

AVTX : 11.54 (-0.86%)
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics Globe Newswire - Mon Aug 1, 2022

Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of...

AVTX : 11.54 (-0.86%)
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split Globe Newswire - Wed Jul 6, 2022

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock...

AVTX : 11.54 (-0.86%)
Avalo to Present at the 2022 Jefferies Healthcare Conference Globe Newswire - Thu Jun 2, 2022

WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D.,...

AVTX : 11.54 (-0.86%)
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA) Globe Newswire - Wed May 18, 2022

Topline results expected 4Q2022...

AVTX : 11.54 (-0.86%)
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference Globe Newswire - Tue May 17, 2022

WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D.,...

AVTX : 11.54 (-0.86%)
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates Globe Newswire - Thu May 5, 2022

Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion...

AVTX : 11.54 (-0.86%)
Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference Globe Newswire - Tue Mar 8, 2022

WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine...

AVTX : 11.54 (-0.86%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 26 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot